JMIR Publications

ABSTRACT

Background:

Asthma and chronic obstructive pulmonary disease (COPD) affect millions of people worldwide. Whilst medication can control and improve disease symptoms, incorrect use of medication is a common problem. eHealth intervention ‘SARA’ aims to improve participants’ correct use of inhalation medication by providing information, as well as as-needed tailored follow-up support by a pharmacist.

Objective:

The primary aim of this study was to investigate the effect of SARA on exacerbation rates in participants with asthma and COPD. Secondary aims were to investigate its effects in terms of adherence to maintenance medication and antimycotic treatment.

Methods:

In this non-randomized pre-post study, medication dispensing data of 382 Dutch community pharmacies were included. Exacerbation rates were assessed with dispensed oral corticosteroids short courses. Medication adherence was assessed by calculating the proportion of days covered (PDC) from dispensed inhalation maintenance medication, wherefore a distinction was made between new and chronic users. Antimycotic treatment was investigated from dispensed oral antimycotics in participants who were also dispensed inhaled corticosteroids (ICS). Outcomes were assessed one year before and one year after implementation of SARA and compared between SARA participants and control participants. More specifically, for exacerbation rates and medication adherence, a difference score was calculated (year after SARA minus year before SARA), and subsequently compared between the study groups with independent samples t-tests. For antimycotics, the relative number of participants who were dispensed antimycotics was calculated and subsequently analyzed with a mixed-effects logistic regression

Results:

The study population comprised 9,452 participants, of whom 2,400 were SARA participants. The mean age of the population was about 61, and approximately two-third was female. The results showed an increase in mean exacerbation rates over time for both study groups; 0.05 increase in SARA and 0.15 in controls. However this increase in exacerbations was significantly lower in the SARA condition (t9450= 3.10, 95% CI= 0.04 – 0.16, P= .002, Cohen d = 0.06). Chronic users of inhalation medication showed an increase in medication adherence over time in both study groups (6.73 in SARA and 4.48 control participants respectively); yet, this increase was significantly higher for SARA participants (t5886= -2.74, 95% CI= -3.86 – -0.84, P=.01, Cohen d = -0.07). In new users of inhalation medication, results showed no significant difference in medication adherence between SARA and controls in the year after implementation of SARA (t1434= -1.85, 95% CI= -5.60 – 0.16, P=.06, Cohen d = -0.10). In ICS-users, no significant differences between the study groups were found over time in terms of the proportion of participants who were dispensed antimycotics (t5654= 0.29, 95% CI= -0.40 - 0.54, P=.76, Cohen d = 0.00).

Conclusions:

This study provides preliminary evidence that eHealth intervention SARA might have the potential to decrease exacerbation rates and improve medication adherence.